Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) CEO Peter Salzmann sold 28,094 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $12.99, for a total transaction of $364,941.06. Following the completion of the transaction, the chief executive officer now directly owns 1,186,512 shares of the company's stock, valued at approximately $15,412,790.88. The trade was a 2.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Peter Salzmann also recently made the following trade(s):
- On Wednesday, January 15th, Peter Salzmann sold 8,767 shares of Immunovant stock. The shares were sold at an average price of $23.83, for a total value of $208,917.61.
Immunovant Stock Performance
Immunovant stock opened at $14.68 on Friday. The stock has a 50-day simple moving average of $18.57 and a 200 day simple moving average of $24.06. The stock has a market capitalization of $2.49 billion, a P/E ratio of -5.60 and a beta of 0.81. Immunovant, Inc. has a 52 week low of $12.72 and a 52 week high of $34.47.
Immunovant (NASDAQ:IMVT - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.08). Research analysts forecast that Immunovant, Inc. will post -2.69 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on IMVT shares. Wolfe Research lowered Immunovant from an "outperform" rating to a "peer perform" rating in a research report on Friday, January 3rd. Bank of America cut their price objective on shares of Immunovant from $38.00 to $33.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Wells Fargo & Company decreased their target price on shares of Immunovant from $47.00 to $45.00 and set an "overweight" rating for the company in a research report on Thursday, December 19th. Guggenheim reissued a "buy" rating on shares of Immunovant in a research report on Thursday, March 20th. Finally, Cantor Fitzgerald upgraded Immunovant to a "strong-buy" rating in a report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Immunovant currently has a consensus rating of "Buy" and an average target price of $41.00.
Check Out Our Latest Research Report on Immunovant
Hedge Funds Weigh In On Immunovant
Several institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC boosted its holdings in shares of Immunovant by 4.5% during the 4th quarter. FMR LLC now owns 13,097,915 shares of the company's stock worth $324,435,000 after buying an additional 560,344 shares during the period. Vanguard Group Inc. lifted its position in Immunovant by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 6,679,414 shares of the company's stock worth $165,449,000 after acquiring an additional 20,614 shares during the last quarter. Deep Track Capital LP boosted its holdings in shares of Immunovant by 38.0% during the fourth quarter. Deep Track Capital LP now owns 6,000,000 shares of the company's stock worth $148,620,000 after acquiring an additional 1,652,536 shares during the period. T. Rowe Price Investment Management Inc. grew its position in shares of Immunovant by 53.6% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,117,234 shares of the company's stock valued at $126,754,000 after purchasing an additional 1,786,217 shares during the last quarter. Finally, State Street Corp grew its position in shares of Immunovant by 11.2% in the third quarter. State Street Corp now owns 3,022,342 shares of the company's stock valued at $86,167,000 after purchasing an additional 303,386 shares during the last quarter. 47.08% of the stock is currently owned by institutional investors and hedge funds.
About Immunovant
(
Get Free Report)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
